{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:08:59Z","timestamp":1780351739292,"version":"3.54.1"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapies, especially the programmed cell death 1\/programmed cell death ligand 1 (PD-1\/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers. As for colorectal cancer (CRC), the current clinical application of PD-1\/PD-L1 inhibitors are mainly used according to the mutation pattern, which is categorized into deficient mismatch repair (dMMR)\/high levels of microsatellite instability (MSI-H) and proficient mismatch repair (pMMR), or non-high levels of microsatellite instability (non-MSI-H). PD-1\/PD-L1 inhibitors have been proven to have favorable outcomes against dMMR\/MSI-H CRC because of more T-cell infiltration into tumor tissues. Nevertheless, the effectiveness of PD-1\/PD-L1 inhibitors in pMMR\/non-MSI-H CRC is still uncertain. Because of the quite-lower proportion of dMMR\/MSI-H in CRC, PD-1\/PD-L1 inhibitors have been reported to combine with other antitumor treatments including chemotherapy, radiotherapy, and targeted therapy for better therapeutic effect in recent clinical trials. Neoadjuvant therapy, mainly including chemotherapy and radiotherapy, not only can reduce clinical stage but also benefit from local control, which can improve clinical symptoms and the quality of life. Adding immunotherapy into neoadjuvant therapy may change the treatment strategy of primary resectable or some metastatic CRC. In this review, we focus on the development of neoadjuvant anti-PD-1\/PD-L1 therapy and discuss the future perspectives in CRC.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1001444","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T17:20:56Z","timestamp":1662744056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Current progress and future perspectives of neoadjuvant anti-PD-1\/PD-L1 therapy for colorectal cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhengyang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guocong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.789330","article-title":"Opportunities and challenges of nanoparticles in digestive tumours as anti-angiogenic therapies","volume":"11","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i20.6113","article-title":"Role of surgery in colorectal cancer liver metastases","volume":"20","author":"Akg\u00fcl","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.080","article-title":"Clinical implications of colorectal cancer stem cells in the age of single-cell omics and targeted therapies","volume":"160","author":"Frank","year":"2021","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: Rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: A review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the united states and united kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41423-021-00735-3","article-title":"IFN\u03b3 signaling integrity in colorectal cancer immunity and immunotherapy","volume":"19","author":"Du","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.005","article-title":"Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front","volume":"182","author":"Sch\u00fcrch","year":"2020","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.058","article-title":"Innate immune training of granulopoiesis promotes anti-tumor activity","volume":"183","author":"Kalafati","year":"2020","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41590-021-01125-7","article-title":"PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity","volume":"23","author":"Sugiura","year":"2022","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12957-022-02549-7","article-title":"Clinical benefits of PD-1\/PD-L1 inhibitors in patients with metastatic colorectal cancer: A systematic review and meta-analysis","volume":"20","author":"Zhang","year":"2022","journal-title":"World J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102174","article-title":"A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research","volume":"95","author":"Wensink","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0414-4","article-title":"Deficient mismatch repair and the role of immunotherapy in metastatic colorectal cancer","volume":"17","author":"Quiroga","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030618","article-title":"Immunotherapy, inflammation and colorectal cancer","volume":"9","author":"Lichtenstern","year":"2020","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-Instability-High advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA Approval summary: Pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.04.004","article-title":"Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: A diagnostic systematic review and meta-analysis","volume":"14","author":"de Gouw","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2018.04.053","article-title":"Neoadjuvant therapy or upfront surgery? a systematic review and meta-analysis of T2N0 esophageal cancer treatment options","volume":"54","author":"Mota","year":"2018","journal-title":"Int J Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003620","article-title":"Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study","volume":"18","author":"Tie","year":"2021","journal-title":"PLoS Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003741","article-title":"Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study","volume":"18","author":"Wang","year":"2021","journal-title":"PLoS Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7150\/jca.48337","article-title":"Adding adjuvants to fluoropyrimidine-based neoadjuvant chemoradiotherapy for locally advanced rectal cancer: An option worthy of serious consideration","volume":"12","author":"Wu","year":"2021","journal-title":"J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638873","article-title":"Optimizing the treatment schedule of radiotherapy combined with anti-PD-1\/PD-L1 immunotherapy in metastatic cancers","volume":"11","author":"Kong","year":"2021","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.11.132","article-title":"Stromal PD-L1-Positive regulatory T cells and PD-1-Positive CD8-positive T cells define the response of different subsets of non-small cell lung cancer to PD-1\/PD-L1 blockade immunotherapy","volume":"13","author":"Wu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.canlet.2019.08.005","article-title":"Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer","volume":"464","author":"Fournel","year":"2019","journal-title":"Cancer Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.764618","article-title":"Progress in the application of immune checkpoint inhibitor-based immunotherapy for targeting different types of colorectal cancer","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107694","article-title":"Combination therapy with PD-1\/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms","volume":"219","author":"Huang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.769124","article-title":"Research progress of anti-PD-1\/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC","volume":"12","author":"Bie","year":"2022","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.04.004","article-title":"DNA Mismatch repair in cancer","volume":"189","author":"Baretti","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1907","article-title":"The multifaceted mismatch-repair system","volume":"7","author":"Jiricny","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2019.03.009","article-title":"The mismatch repair-dependent DNA damage response: Mechanisms and implications","volume":"78","author":"Gupta","year":"2019","journal-title":"DNA Repair (Amst)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1046022","article-title":"The interplay between DNA repair and autophagy in cancer therapy","volume":"16","author":"Zhang","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1245\/s10434-020-08209-y","article-title":"MMR deficiency is homogeneous in pancreatic carcinoma and associated with high density of Cd8-positive lymphocytes","volume":"27","author":"Fraune","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90546-3","article-title":"The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer","volume":"75","author":"Fishel","year":"1993","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2899","article-title":"Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: A pooled analysis from 2 randomized clinical trials","volume":"4","author":"Zaanan","year":"2018","journal-title":"JAMA Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06992-9","article-title":"Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis","volume":"49","author":"Cevik","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173819","article-title":"Current advancements and future perspectives of immunotherapy in colorectal cancer research","volume":"893","author":"Kishore","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188447","article-title":"Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside","volume":"1874","author":"Lizardo","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"djv438","DOI":"10.1093\/jnci\/djv438","article-title":"Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: A Large multicenter AGEO study","volume":"108","author":"Tougeron","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ctrv.2016.10.005","article-title":"The evolving role of microsatellite instability in colorectal cancer: A review","volume":"51","author":"Gelsomino","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795972","article-title":"Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: New strategies and unveiled opportunities","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: A systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.07.023","article-title":"Current status and future perspective of immune checkpoint inhibitors in colorectal cancer","volume":"521","author":"Zhou","year":"2021","journal-title":"Cancer Lett"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-High\/Mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64077","article-title":"Immunotherapy in colorectal cancer: Current achievements and future perspective","volume":"17","author":"Fan","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003051","article-title":"Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: A national cancer database (NCDB) analysis","volume":"271","author":"Hasan","year":"2020","journal-title":"Ann Surg"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.799957","article-title":"The research progress of PD-1\/PD-L1 inhibitors enhancing radiotherapy efficacy","volume":"11","author":"Wen","year":"2021","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28499","article-title":"Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression","volume":"3","author":"Deng","year":"2014","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003554","article-title":"Single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: Initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12885-022-09554-9","article-title":"Rationale and design of a prospective, multicenter, p II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01738-6","article-title":"Apparent diffusion coefficient for the prediction of tumor response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer","volume":"16","author":"Zhao","year":"2021","journal-title":"Radiat Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2020.11.009","article-title":"Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"144","author":"Colle","year":"2021","journal-title":"Eur J Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010120","article-title":"Comparison of RECIST 1.1 and iRECIST in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"13","author":"Park","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"B86","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2274","article-title":"Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy","volume":"1","author":"Lo","year":"2015","journal-title":"JAMA Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa200","article-title":"Current status and perspectives of immune checkpoint inhibitors for colorectal cancer","volume":"51","author":"Hirano","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225.Erratumin:AnnOncol","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1001444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T17:20:59Z","timestamp":1662744059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1001444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2022.1001444"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1001444","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"article-number":"1001444"}}